Finoriq research workspace
Assertio Holdings, Inc. (ASRT) Company Overview
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United. Review ASRT filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
- Company
- Assertio Holdings, Inc. (ASRT)
- Ticker
- ASRT
- Market Cap
- $151.8M
- Latest Price
- $23.5
- Industry
- Biotech & Pharma
Assertio Holdings, Inc. (ASRT) Current Valuation Metrics
Static valuation preview for Assertio Holdings, Inc. (ASRT). Market data retrieved 2026-06-15. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 1.28x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -20.0% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -18.6% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 1.62x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.